利拉鲁肽对肥胖青少年的体重改善效果无法持久。 - Suppr

Suppr

超能文献

Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.

作者信息

Brady Clare, Shaikh M Guftar

机构信息

General Paediatrics, Royal Hospital for Children, Glasgow, UK

Endocrinology, Royal Hospital for Sick Children, Glasgow, Glasgow, UK.

出版信息

Arch Dis Child Educ Pract Ed. 2022 Jun;107(3):232. doi: 10.1136/archdischild-2020-319807. Epub 2020 Sep 28.

DOI:10.1136/archdischild-2020-319807

PMID:32988963

Abstract

摘要

相似文献

Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.

Arch Dis Child Educ Pract Ed. 2022 Jun;107(3):232. doi: 10.1136/archdischild-2020-319807. Epub 2020 Sep 28.

Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.

J Pediatr. 2017 Feb;181:146-153.e3. doi: 10.1016/j.jpeds.2016.10.076. Epub 2016 Dec 13.

Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents.

J Pediatr Endocrinol Metab. 2021 Apr 7;34(5):613-618. doi: 10.1515/jpem-2020-0714. Print 2021 May 26.

Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.

Pediatr Obes. 2019 May;14(5):e12495. doi: 10.1111/ijpo.12495. Epub 2019 Jan 17.

Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.

Curr Obes Rep. 2020 Dec;9(4):391-401. doi: 10.1007/s13679-020-00409-7. Epub 2020 Oct 21.

The safety of pharmacologic treatment for pediatric obesity.

Expert Opin Drug Saf. 2018 Apr;17(4):379-385. doi: 10.1080/14740338.2018.1437143. Epub 2018 Feb 7.

Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.

Lancet Gastroenterol Hepatol. 2017 Dec;2(12):890-899. doi: 10.1016/S2468-1253(17)30285-6. Epub 2017 Sep 27.

The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.

Br J Dermatol. 2017 Sep;177(3):858-859. doi: 10.1111/bjd.15233. Epub 2017 Jul 14.

The Current Role of Liraglutide in the Pharmacotherapy of Obesity.

Curr Vasc Pharmacol. 2016;14(2):201-7. doi: 10.2174/1570161113666150615111951.

Liraglutide for Type 2 diabetes and obesity: a 2015 update.

Expert Rev Cardiovasc Ther. 2015;13(7):753-67. doi: 10.1586/14779072.2015.1054810.

引用本文的文献

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Children (Basel). 2023 Jan 25;10(2):208. doi: 10.3390/children10020208.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.

作者信息

Brady Clare, Shaikh M Guftar

机构信息

General Paediatrics, Royal Hospital for Children, Glasgow, UK

Endocrinology, Royal Hospital for Sick Children, Glasgow, Glasgow, UK.

出版信息

Arch Dis Child Educ Pract Ed. 2022 Jun;107(3):232. doi: 10.1136/archdischild-2020-319807. Epub 2020 Sep 28.

DOI:10.1136/archdischild-2020-319807

PMID:32988963

Abstract

摘要

相似文献

Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.

Arch Dis Child Educ Pract Ed. 2022 Jun;107(3):232. doi: 10.1136/archdischild-2020-319807. Epub 2020 Sep 28.

J Pediatr. 2017 Feb;181:146-153.e3. doi: 10.1016/j.jpeds.2016.10.076. Epub 2016 Dec 13.

Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents.

J Pediatr Endocrinol Metab. 2021 Apr 7;34(5):613-618. doi: 10.1515/jpem-2020-0714. Print 2021 May 26.

Pediatr Obes. 2019 May;14(5):e12495. doi: 10.1111/ijpo.12495. Epub 2019 Jan 17.

Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.

Curr Obes Rep. 2020 Dec;9(4):391-401. doi: 10.1007/s13679-020-00409-7. Epub 2020 Oct 21.

The safety of pharmacologic treatment for pediatric obesity.

Expert Opin Drug Saf. 2018 Apr;17(4):379-385. doi: 10.1080/14740338.2018.1437143. Epub 2018 Feb 7.

Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.

Lancet Gastroenterol Hepatol. 2017 Dec;2(12):890-899. doi: 10.1016/S2468-1253(17)30285-6. Epub 2017 Sep 27.

The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.

Br J Dermatol. 2017 Sep;177(3):858-859. doi: 10.1111/bjd.15233. Epub 2017 Jul 14.

The Current Role of Liraglutide in the Pharmacotherapy of Obesity.

Curr Vasc Pharmacol. 2016;14(2):201-7. doi: 10.2174/1570161113666150615111951.

Liraglutide for Type 2 diabetes and obesity: a 2015 update.

Expert Rev Cardiovasc Ther. 2015;13(7):753-67. doi: 10.1586/14779072.2015.1054810.

引用本文的文献

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Children (Basel). 2023 Jan 25;10(2):208. doi: 10.3390/children10020208.